Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

Summary

Patients with either histological confirmation or clinical diagnosis who are candidate for orthotopic liver transplant(OLT) will receive Sorafenib 400mg 2 x day (BID) as a neoadjuvant (bridging) treatment until transplant. If patient progresses or falls outside of the Milan criteria on sorafenib patient can be treated per physician's discretion using local therapy. Patient will be followed until 30 days after the orthotopic liver transplant (OLT).

Timeline

Start

2010-09

Primary completion

2011-05

Completion

2012-01

Drugs

Indications